A stable tubal ectopic with a rising hCG: methotrexate or surgery?
A 29-year-old woman, G2P1, presents to the early pregnancy unit with five days of light vaginal spotting and intermittent left iliac fossa pain. Her last menstrual period was seven weeks ago and a home pregnancy test was positive ten days ago. She is haemodynamically stable and afebrile with mild left adnexal tenderness and no guarding; haemoglobin is 118 g/L. Transvaginal ultrasound shows an empty uterus with a thickened endometrium, a 22 mm left adnexal mass with a 'bag of rings' appearance and no fetal cardiac activity, and no free fluid in the pouch of Douglas. Serum hCG is 1750 IU/L and 48 hours later is 2300 IU/L; progesterone is 8 nmol/L. Liver and renal function are normal. She is a non-smoker and is anxious to avoid surgery because she has one child and wants more.
1. Is she a suitable candidate for methotrexate? Assess her against the criteria and explain your reasoning.
Read the worked answer
She meets most criteria but the trend in hCG makes her an intermediate candidate rather than an ideal one.
Criteria favouring methotrexate
- Haemodynamically stable, no signs of rupture or significant haemoperitoneum, able to be monitored.
- Mass 22 mm - below the usual 35–40 mm threshold.
- No fetal cardiac activity.
- Normal renal, hepatic and haematological function; no breastfeeding, no immunodeficiency.
- hCG 1750 IU/L - below the commonly used 1500–5000 IU/L range, though success falls steadily as hCG rises.
Features against
- The hCG is rising - from 1750 to 2300, an increase of about 31% in 48 hours. Rapidly rising hCG is the strongest predictor of methotrexate failure, because a viable, actively dividing trophoblast is present. Success at this level is perhaps 60–70%, with a meaningful chance of needing a second dose and roughly 10–15% ultimately needing surgery.
- Her strong preference for avoiding surgery is understandable but is not a medical criterion; she must be counselled that methotrexate is not a guarantee and that surgery remains possible.
What I would do - offer both options explicitly. Single-dose methotrexate with rigorous follow-up is defensible if she accepts the need for repeated blood tests, the risk of rupture during treatment and the possibility of a second dose or surgery. Laparoscopic salpingectomy is definitive, has a high success rate, and does not reduce her fertility if the other tube is healthy; salpingostomy preserves the tube but carries a 5–20% risk of persistent trophoblast. Given the rising hCG and her wish for future fertility, she should not be steered towards methotrexate without being told that surgery is at least as good a choice. Before either option, confirm her blood group and check for anti-D need according to local policy.
2. She chooses methotrexate. Give the regimen, the follow-up schedule, the definition of success, and what you would do if the response is inadequate.
Read the worked answer
Regimen - methotrexate 50 mg/m² by intramuscular injection as a single dose, calculated from her height and weight. Before giving it, recheck full blood count, urea, creatinine, liver enzymes, and confirm she is not breastfeeding. Exclude a coexisting intrauterine pregnancy (already done on scan) and check the blood group.
Advice at the time of injection
- Avoid folate supplements, non-steroidal anti-inflammatory drugs, alcohol and excessive sun exposure during treatment.
- Report severe abdominal pain, shoulder-tip pain, dizziness or heavy bleeding immediately - rupture can occur even while the hCG is falling.
- Avoid strenuous activity and intercourse until the hCG is undetectable, and use reliable contraception for at least three months afterwards because methotrexate is teratogenic.
Follow-up
- hCG on day 0 (before the dose), day 4 and day 7.
- The hCG often rises between day 0 and day 4; this is expected and does not mean failure.
- Success is a fall of at least 15% between day 4 and day 7. If that is achieved, repeat hCG weekly until it is below 5 IU/L.
- Inadequate response - less than a 15% fall from day 4 to day 7 - is an indication for a second dose of 50 mg/m², with the same day 4/day 7 monitoring repeated after it. If the hCG plateaus or rises after a second dose, or if she develops pain, free fluid, a significant haemoglobin fall or any sign of rupture at any stage, proceed to surgery.
- Warn her that about one in five women need more than one dose and that treatment takes several weeks, with hospital visits throughout.
Safety net - give her a written early pregnancy unit contact number and a clear instruction to attend the emergency department if pain becomes severe. Document the discussion about the risk of rupture and the plan for surgical rescue.
3. She asks about her future fertility and the risk of this happening again, and whether surgery would have damaged her chances. What do you tell her?
Read the worked answer
Fertility after ectopic pregnancy is good. Most women conceive again. The key determinant is the state of the tubes, not which treatment was used.
- After salpingectomy, if the remaining tube and ovary are normal, spontaneous conception rates are not reduced compared with the general population in most series, and IVF success is unaffected.
- After methotrexate, fertility is also preserved; the drug does not reduce ovarian reserve at the doses used. It avoids surgery, but it takes weeks to resolve and carries the small risk of rupture during treatment.
- Randomised comparisons of methotrexate and surgery generally show similar subsequent intrauterine pregnancy rates, so her choice should be based on safety, follow-up burden and certainty, not on a belief that one protects fertility more than the other.
Recurrence risk - about 10–15% after one ectopic, higher if there is known tubal damage, previous pelvic infection, smoking (she does not smoke) or a history of infertility. She should have an early transvaginal scan at 6–7 weeks in any future pregnancy to confirm the pregnancy is intrauterine, and she should contact the unit as soon as she has a positive test rather than waiting for a routine appointment.
If surgery is needed - salpingectomy is preferred if the contralateral tube is healthy; salpingostomy is reserved for a woman with a damaged or absent contralateral tube, but it requires hCG follow-up because of persistent trophoblast.
Practical points - discuss a plan for contraception now, since she will need to avoid pregnancy for three months after methotrexate, and note that a copper or progestogen-only method can be started early. Give written information, arrange a follow-up appointment to review the hCG trend and to answer further questions, and offer bereavement support - she has lost a pregnancy, and her anxiety about the future deserves acknowledgment as well as information.